

## CURRICULUM VITAE

Date Prepared: 6 May 2003

Name: Andrew A. Renshaw

Address: Department of Pathology  
Baptist Hospital of Miami  
8900 N. Kendall Dr.  
Miami, FL 33176

Tel: 305 596 6525  
Fax 305 598 5986

### Education:

B.S. Massachusetts Institute of Technology  
M.D. Harvard Medical School, Harvard-MIT Division of Health Sciences

### Postdoctoral Training:

Intern in Medicine, Brigham & Women's Hospital, Boston, MA  
Resident in Anatomic & Clinical Pathology, Brigham & Women's Hospital, Boston,  
MA  
Rotating Fellow, Memorial Sloan-Kettering Cancer Center, NY, NY  
Chief Resident, Anatomic Pathology, Brigham & Women's Hospital  
Fellow in Cytology, Brigham & Women's Hospital, Boston, MA

### Licensure & Certification:

National Board of Medical Examiners  
American Board of Pathology (Anatomic & Clinical Pathology)  
Massachusetts Board of Registration in Medicine License  
American Board of Pathology (Cytopathology)  
Florida Board of Registration in Medicine

### Academic Appointments:

Clinical Fellow in Medicine, Harvard Medical School  
Clinical Fellow in Pathology, Harvard Medical School  
1995 Instructor in Pathology, Harvard Medical School  
1996-1998 Assistant Professor, Harvard Medical School

### Hospital Appointments:

1998 Pathologist, Baptist Hospital of Miami  
1995-1998 Director, Urologic Pathology, Brigham & Women's Hospital  
1995-1998 Associate Pathologist, Brigham & Women's Hospital  
1995-1998 Associate, Fine Needle Aspiration Service, Brigham & Women's Hospital

### Other Appointments:

- 2002- Chairperson, Food & Drug Administration, Hematology and Pathology Devices Panel  
2001- American Society of Cytopathology Scientific Program Committee  
1998- Food & Drug Administration, Hematology and Pathology Devices Panel  
1998- College of American Pathologists Cytopathology Committee

Awards & Honors:

Phi Beta Kappa  
Sigma Xi, Scientific Research Society  
National Merit Scholarship

Professional Association Memberships:

- 1995 New England Society of Pathologists  
1995 Urologic Pathology Society  
1994 American Society of Clinical Pathologists  
1994 American Society of Cytopathology  
1994 United States and Canadian Academy of Pathology  
1992 College of American Pathologists

Book Editor:

Advances in Anatomic Pathology

Editorial Board:

American Journal of Clinical Pathology  
Cancer Cytopathology  
Journal of Urologic Pathology

Reviewer:

American Journal of Clinical Pathology  
American Journal of Pathology  
American Journal of Surgical Pathology  
Applied Immunohistochemistry  
Archives of Pathology and Laboratory Medicine  
Cancer  
Cancer Cytopathology  
Cancer Detection and Prevention  
European Journal of Cancer  
Journal of Pathology  
Journal of Urologic Pathology  
Journal of Clinical Microbiology  
Laboratory Investigation  
Modern Pathology  
Oncogene  
The Prostate Journal  
Urology

Other:

1997 American Society of Cytopathology Local Arrangements Committee

1999-2002 US and Canadian Academy of Pathology Abstract Review Board

**Major Research Interests:**

1. Genitourinary pathology
2. Cytopathology

**Self Report of Teaching:**

American Society of Cytopathology Teleconference, March 25, 2003

Measuring Performance in Gynecologic Cytology

Lecturer

60 sites

1 hour

American Society of Cytopathology Annual Meeting, Salt Lake City, UT, 2002

State of the Art Symposium: Can one diagnose low grade urothelial lesions?

Lecturer

500 people

3 hrs

Diagnostic Cytology Seminar

Lecturer

500 people

1.5 hrs

American Society of Clinical Pathologists

2000 Teleconference series

Lecturer, Pitfalls in Renal FNA

70 sites,

1 hr

Florida State Society of Cytology

2000 Annual Scientific Meeting

Lecturer, Urinary Cytology, Renal FNA

100 Cytopathologists and cytotechnologists

2 hrs/yr

Baptist Hospital of Miami

1999 Medical Grand Rounds

Lecturer, Pathology of Prostate Cancer

30 Clinicians

1 hr/yr

1999-2000 National Laboratory Week Annual Symposium

Lecturer, Urine Cytology, Renal FNA

20 Medical technologists  
1hr/yr

United States and Canadian International Association of Pathologists  
1999      George Papanicolaou Society Conference  
              Lecturer, Pitfalls in Renal FNA  
              200 pathologists, fellows, and staff  
              1 hr/yr

1998      Genitourinary Slide Conference  
              Lecturer  
              200 pathologists, fellows and staff  
              2 hours/year

Brigham & Women's Hospital

1995-98     Urology Residents Review  
              Lecturer  
              15 residents/fellows  
              8 hours/year

1995-96     Pulmonary Fellows Review Course  
              Lecturer  
              6 fellows  
              2 hours/year

Harvard Medical School

1996-2002    Advances in Cytology  
              Lecturer on Urinary Cytology and FNA of Adult Kidney  
              130 cytologists and cytotechnologists  
              8 hours/yr

1996-98     Human Systems Endocrine Pathophysiology Course  
              CPC Lecturer on Prostate Pathology  
              150 medical students  
              1 hour/year

1995        Advances in Cytology, Pulmonary Cytology  
              Lecturer  
              130 cytologists and cytotechnologists  
              2 hours/yr

- 1994 Human Systems Course, Pathology of Bone & Joints  
Laboratory Instructor  
20 medical students  
12 hours/year
- 1994 HST Introduction to Clinical Medicine  
Teaching Assistant  
15 medical students  
20 hours/year
- 1991-1992 HST Pathology  
Laboratory Instructor  
30 medical students  
40 hours/year

Massachusetts Institute of Technology

- 1984 Introductory Biology Laboratory (7.011)  
Laboratory Instructor  
30 undergraduates  
100 hours/year

## Publications:

## Original Articles:

1. Von Borstel RW, Renshaw AA, Wurtman RJ. Adenosine strongly potentiates pressor responses to nicotine in rats. *PNAS* 1984; 81: 5599-5603.
2. Gerhart TN, Renshaw AA, Miller RL, Noecker RJ, Hayes WC. In vivo histologic and biomechanical characterization of a biodegradable particulate composite bone cement. *Journal of Biomedical Materials Research* 1989; 23: 1-16.
3. Gerhart TN, Roux RD, Hanff PA, Horowitz GL, Renshaw AA, Hayes WC. Antibiotic-loaded biodegradable bone cement for prophylaxis and treatment of experimental osteomyelitis in rats. *J Ortho Res* 1993; 11: 250-255.
4. Renshaw AA, and Rosai J. Benign atypical vascular lesions of the lip. A study of 12 cases. *Am J Surg Pathol* 1993; 17: 557-565.
5. Renshaw AA, Pinkus GS, Corson JM. CD34 and AE1/AE3. diagnostic discriminants in the diagnosis of solitary fibrous tumor of the pleura and sarcomatoid mesothelioma. *Appl Immunohistochem* 1994; 2: 94-102.
6. Renshaw AA. The relative sensitivity of special stains and culture in open lung biopsies. *Am J Clin Pathol* 1994; 102: 736-740.
7. Renshaw AA, Corless CL. Papillary renal cell carcinoma. Histology and immunohistochemistry. *Am J Surg Pathol* 1995; 19: 842-849.
8. Renshaw AA, Paulus W, Joseph, JT. CD34 and epithelial membrane antigen distinguish dural hemangiopericytoma and meningioma. *Appl Immunohistochem*, 1995; 3: 108-114.
9. Renshaw AA, Nappi D, Weinberg, DS. The cytology of grade 1 papillary transitional cell carcinoma: a comparison of cytologic, architectural, and morphometric criteria in cystoscopically obtained urine. *Acta Cytol* 1996; 40: 676-682.
10. Xiao S, Renshaw A, Cibas ES, Hudson TJ, Fletcher JA. Novel fluorescence in situ hybridization approaches in solid tumors: characterization of frozen specimens, touch preparations, and cytologic preparations. *Am J Pathol*, 1995; 147:896-904.
11. Renshaw AA, Nappi D, Cibas ES. The cytology of prostatic adenocarcinoma in pleural effusions. *Diagn Cytopathol* 1996; 15: 103-107.
12. Renshaw AA. O13 in spindle cell tumors. Reactivity with hemangiopericytoma, solitary fibrous tumor, synovial sarcoma, and meningioma but rarely with sarcomatoid mesothelioma. *Appl Immunohistochem*, 1995; 3:250-256.

13. Fletcher JA, Renshaw AA. Isochrome 7q in adult Wilms tumor. *Cancer Genet Cytogenet*, 1996; 86: 168-169.
14. Renshaw AA, Stelling JM, Doolittle MH. The lack of value of repeated *Clostridium difficile* cytotoxicity assays. *Archiv Pathol Lab Med*, 1996; 120:49-52.
15. Granter SR, Doolittle MH, Renshaw AA. Predominance of neutrophils in the cerebrospinal fluid of AIDS patients with Cytomegalovirus radiculopathy. *Am J Clin Pathol*, 1996; 105: 364-366.
16. Renshaw AA, Granter SR. Fine needle aspiration of chromophobe renal cell carcinoma. *Acta Cytol* 1996; 40: 867-872.
17. Renshaw AA, Doolittle MH. The value of Gram's stain of cell block material from peritoneal fluid in bacterial peritonitis. *Acta Cytol* 1997; 41: 755-758.
18. Renshaw AA, Lee KR, Madge R, Granter SR. Accuracy of fine needle aspiration in distinguishing subtypes of renal cell carcinoma. *Acta Cytol* 1997; 41: 987-994.
19. Comiter CV, Renshaw AA, Benson CB, Loughlin KR. "Burned-out" primary testicular cancers: sonographic and pathologic characteristics. *J Urol* 1996; 156: 85-88.
20. Renshaw AA, Maurici D, Fletcher JA. Cytologic and fluorescence in situ hybridization (FISH) examination of metanephric adenoma. *Diagn Cytopathol* 1997; 16: 107-111.
21. Renshaw AA, Maurici D, Fletcher JA. A papillary renal cell carcinoma with rare papillae histologically resembling collecting duct carcinoma. *J Urol Pathol* 1996; 5: 65-74.
22. Jones D, Weinberg DS, Pinkus GP, Renshaw AA. Cytologic diagnosis of primary serous lymphoma. *Am J Clin Pathol* 1996; 106: 359-364.
23. Renshaw AA, Perez-Atayde AR, Fletcher JA, Granter SR. Cytology of typical and atypical Ewing's sarcoma/PNET. *Am J Clin Pathol* 1996; 106: 620-624.
24. D'Amico AV, Whittington R, Malkowicz SB, Loughlin K, Schultz D, Schnall M, Tempany CM, Tomaszewski JE, Renshaw A, Wein A. An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy. *Urology* 1996; 47: 538-547.
25. Granter SR, Renshaw AA, Fletcher CDM, Bahn AK, Rosenberg AE. CD99 reactivity in mesenchymal chondrosarcoma. *Hum Pathol* 1996; 27: 1273-1276.

26. Renshaw AA, Madge R, Granter SR. Intracytoplasmic eosinophilic inclusions (Melamed-Wolinska bodies) are associated with metastatic transitional cell carcinoma in pleural fluid. *Acta Cytol* 1997; 41: 995-998.
27. Olumi AF, Garnick MB, Renshaw AA, Benson CA, Richie JP. Leydig cell hyperplasia mimicking testicular neoplasm. *Urology* 1996; 48: 647-649.
28. Huang SF, Xiao S, Renshaw AA, Loughlin KR, Hudson TJ, Fletcher JA. Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer. *Am J Pathol* 1996; 149: 1565-1573.
29. Jones D, Renshaw AA. Recurrent crystal-storing histiocytosis of the lung in a patient without a clonal lymphoproliferative disorder. *Archiv Pathol Lab Med* 1996; 120: 978-980.
30. Renshaw AA, Madge R. Cercariform cells help distinguish fine needle aspirates of transitional cell carcinoma from non-small cell lung carcinoma. *Acta Cytol* 1997; 41: 999-1007.
31. Renshaw AA, Henske EP, Loughlin KR, Shapiro C, Weinberg DS. Aggressive variants of chromophobe renal cell carcinoma. *Cancer* 1996; 78: 1756-1761.
32. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. *Chest* 1997; 111: 106-109.
33. Renshaw AA. Adequate tissue sampling of prostate core needle biopsies. *Am J Clin Pathol* 1997; 107: 26-29.
34. Renshaw AA, Nappi D, Swanson S, Sugarbaker DJ. Effusion cytology after extrapleural pneumonectomy for malignant mesothelioma. *Am J Clin Pathol* 1997; 107: 206-210.
35. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional prognostic parameters in 62 cases. *Am J Surg Pathol* 1997; 21: 621-635.
36. Renshaw AA, Chang H, D'Amico AV. An abbreviated protocol for processing radical prostatectomy specimens. Analysis of tumor grade, stage, margin status, and volume. *J Urol Pathol* 1996; 5: 183-192.
37. D'Amico AV, Chang H, Holupka E, Renshaw A, Desjardens A, Chen M, Loughlin KR, Richie JP. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. *Urology* 1997; 49: 385-391.

38. Steele GS, Fielding JR, Renshaw A, Loughlin KR. Transitional cell carcinoma of the fossa navicularis. *Urology* 1997; 50: 792-795.
39. Renshaw AA, Chang H, D'Amico AV. Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. *Am J Clin Pathol* 1997; 107: 704-708.
40. Freeman MR, Yoo JJ, Raab G, Soker S, Schneck FX, Renshaw AA, Klagsbrun M, Atala A. Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized within three cellular compartments in the human bladder. *J Clin Invest* 1997; 99: 1028-1036.
41. Goldstein ML, Whitman T, Renshaw AA. Significance of cell groups in voided urine. *Acta Cytol* 1998; 42: 290-294.
42. Krane JF, Renshaw AA. Relative value and cost effectiveness of culture and special stains in fine needle aspirates of the lung. *Acta Cytol* 1998; 42: 305-311.
43. Renshaw AA, Fletcher JA. Trisomy 3 in renal cell carcinoma. *Mod Pathol* 1997; 10: 481-484.
44. Renshaw AA, Granter SR. Appropriate follow-up interval for biopsy confirmation of squamous intraepithelial lesions diagnosed by cervical smear cytology. *Am J Clin Pathol* 1997; 108: 275-279.
45. Granter SR, Renshaw AA. Fine needle aspiration of chromophobe renal cell carcinoma: analysis of 6 cases. *Cancer Cytopathol* 1997; 81: 122-128.
46. Renshaw AA, Granter SR, Cibas ES. Fine needle aspiration of the adult kidney. *Cancer Cytopathol* 1997; 81: 71-88.
47. Renshaw AA, Zhang H, Corless CL, Fletcher JA, Pins MA. Solid variants of papillary (chromophil) renal cell carcinoma: clinicopathologic and genetic features. *Am J Surg Pathol* 1997; 21: 1203-1209.
48. Renshaw AA. Analysis of error in calculating the false negative rate for interpretation of cervicovaginal smears: the need to review abnormal cases. *Cancer Cytopathol* 1997; 81: 264-271.
49. Renshaw AA, Gordon M, Corless CL. Unclassified sex cord-stromal tumors of the testis with a predominance of spindle cells. Granulosa cell differentiation and reactivity for S-100 protein and smooth muscle actin. *Mod Pathol* 1997; 10: 693-700.
50. Renshaw AA, Dean BR, Cibas EC. Receiver operating characteristic curves (ROCs) for analysis of the results of cervicovaginal smears: a useful quality improvement tool. *Archiv Pathol Lab Med* 1997; 121: 968-975.

51. Granter SR, Fletcher JA, Renshaw AA. Cytologic and cytogenetic analysis of metanephric adenoma: a report of 2 cases. *Am J Clin Pathol* 1997; 108: 544-549.
52. Renshaw AA, Corless CL. Papillary renal cell carcinoma: gross features and histologic correlates. *J Urol Pathol* 1997; 7: 9-19.
53. Renshaw AA, Lee KR, Granter SR. Use of statistical analysis of cytologic interpretation to determine the causes of interobserver disagreement and in quality improvement. *Cancer Cytopathol* 1997; 81: 212-219.
54. Renshaw AA, DiNisco SA, Minter LJ, Cibas ES. A more accurate measure of the false negative rate of Pap smear screening is obtained by determining the false negative rate of the rescreening process. *Cancer Cytopathol* 1997; 81: 272-276.
55. Renshaw AA, Nappi D, Sugarbaker DJ, Swanson S. Effusion cytology of esophageal carcinoma. *Cancer Cytopathol* 1997; 81: 365-372.
56. Comiter CV, Kibel AS, Richie JP, Nucci MR, Renshaw AA. Prognostic features of teratomas with malignant transformation: a clinicopathologic study of 21 cases. *J Urol* 1998; 159: 859-863.
57. Renshaw AA, Madge R, Sugarbaker DJ, Swanson S. Malignant pleural effusions after resection of pulmonary adenocarcinoma. *Acta Cytol* 1998; 42: 1111-1115.
58. Renshaw AA. Correlation of gross morphology with histology in radical prostatectomy specimens. *Am J Clin Pathol* 1998; 110: 38-42.
59. Dry SM, Renshaw AA. Extensive calcium oxalate crystal deposition in papillary renal cell carcinoma: a report of 2 cases. *Archiv Pathol Lab Med* 1998; 122: 260-261.
60. Renshaw AA, Madge R, Jiroutek M, Granter SR. Bile duct brushing cytology: Statistical analysis of proposed diagnostic criteria. *Am J Clin Pathol* 1998; 110: 635-640.
61. Renshaw AA, Santis WF, Richie JP. Clinicopathologic characteristics of prostatic adenocarcinoma in men with atypical prostate needle biopsies. *J Urol* 1998; 159: 2018-2022.
62. Renshaw AA, Shapiro C, Fletcher JA, Pins MR. An unusual papillary tumor of the renal medulla: distinction from usual papillary renal cell carcinoma and collecting duct carcinoma. *J Urol Pathol* 1998; 8: 121-133.
63. Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV. The maximum diameter of prostatic carcinoma is a simple and inexpensive predictor of PSA failure in radical prostatectomy specimens. *Cancer* 1998; 83: 748-752.

64. Freeman MR, Paul S, Kaefer M, Ishikawa M, Adam RM, Renshaw AA, Elenius K, Klagsbrun M. Heparin binding EGF-like growth factor in human prostate: synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. *J Cell Biochem* 1998; 68: 328-338.
65. Renshaw AA, Comiter CV, Nappi D, Granter SR. Effusion cytology of renal cell carcinoma. *Cancer Cytopathol* 1998; 84: 148-152.
66. Loughlin KR, Renshaw A, Kumar S. Expectant management of stage A-1 (T1a) prostate cancer utilizing serum PSA levels. *J Surg Oncol* 1999; 70: 49-53.
67. Vargas SA, Jiroutek M, Welch WR, Nucci MR, D'Amico AV, Renshaw AA. Perineural invasion in prostate needle biopsies: correlation with extraprostatic extension at resection. *Am J Clin Pathol* 1999; 111: 223-228.
68. D'Amico AV, Desjardin A, Chung A, Chen MH, Schultz D, Whittington R, Malkowicz SB, Wein A, Tomaszewski JE, Renshaw AA, Loughlin K, Richie JP. Assessment of outcome prediction models for localized prostate cancer in patients managed with radical prostatectomy or external beam radiation therapy. *Cancer* 1998; 82: 1887-1896.
69. D'Amico AV, Desjardin A, Chen MH, Paik S, Schultz D, Renshaw AA, Loughlin KR, Richie JP. Analyzing outcome based staging for clinically localized adenocarcinoma of the prostate. *Cancer* 1998; 83: 2172-2180.
70. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Loughlin KR, Richie JP, Wein A. Calculated prostate cancer volume greater than 4.0cm<sup>3</sup> identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external beam. *J Clin Oncol* 1998; 16: 3094-3100.
71. Renshaw AA, Friedman MM, Rahemtulla A, Granter SR, Dean BR, Cronin JA, Jiroutek M, Cibas ES. Accuracy and reproducibility of estimating the adequacy of the squamous component of cervicovaginal smears. *Am J Clin Pathol* 1999; 111:38-42.
72. Gordon MD, Corless C, Renshaw AA, Beckstead J. CD99 (Mic2), keratin, and vimentin staining of sex cord-stromal tumors, normal ovary and testis Mod Pathol 1998; 11: 769-773.
73. Renshaw AA. Testicular calcifications: incidence, histology, and proposed pathologic criteria for testicular microlithiasis. *J Urol* 1998; 160: 1625-1628.
74. Renshaw AA, Morgan TW, Fletcher JA. A sarcomatoid renal cell carcinoma with a "hobnail pattern" and immunohistochemical and cytogenetic features of papillary carcinoma. *J Urol Pathol* 1998; 9: 93-102.

75. Dry SM, Renshaw AA. Germ cell tumors preferentially invade the tunica albuginea at the hilum. *Am J Clin Pathol* 1999; 111: 534-538.
76. Granter SR, Perez-Atayde AR, Renshaw AA. Cytologic analysis of papillary renal cell carcinoma. *Cancer Cytopathol* 1998; 84: 303-308.
77. Renshaw AA, Bellerose B, DiNisco SA, Minter LJ, Lee KR. The false negative rate of Pap smear screening as determined by rapid rescreening. *Acta Cytol* 1999; 43: 344-350.
78. Fielding JR, Aliabadi N, Renshaw AA, Silverman SG. Staging renal cell carcinoma: yield and cost effectiveness of pelvic CT scans. *Am J Roentgenol* 1999; 172: 23-25.
79. Renshaw AA, Loughlin KR, Dutta A. Cyclin A and Mib1 (Ki67) as markers of proliferative activity in primary renal neoplasms. *Mod Pathol* 1998; 11: 963-966.
80. Granter SR, Renshaw AA, Cibas ES. Non-tyrosine crystalloids in fine needle aspiration specimens of the parotid gland: a report of 2 cases and review of the literature. *Diagn Cytopathol* 1998; 20: 44-46.
81. Renshaw AA, Richie JR. Subtypes of renal cell carcinoma: different onset and sites of metastatic disease. *Am J Clin Pathol* 1999; 111: 539-543.
82. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA* 1998; 280: 969-974.
83. Granter SR, Renshaw AA, Kozakewich HP, Fletcher JA. Pericentromeric inversion inv(6)(p25q13) is a novel diagnostic marker in chondromyxoid fibroma. *Mod Pathol* 1998; 11: 1071-1074.
84. Renshaw AA, Cronin JA, Minter LJ, Nappi D, Whitman T, Jiroutek M, Cibas ES. Performance characteristics of rapid (30 second) prescreening: implications for calculating the false-negative rate and comparison with other quality assurance techniques. *Am J Clin Pathol* 1999; 111: 517-522.
85. Rubin BP, Fletcher JA, Renshaw AA. Clear cell sarcoma of soft parts: Report of a case primary in the kidney. *Am J Surg Pathol* 1999; 23: 589-594.
86. Renshaw AA, Granter SR. Comparison of A103 and Inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors. *Mod Pathol* 1998; 11: 1160-1164.
87. Renshaw AA, Richie JP, Loughlin KR, Jirtoutek M, Chung A, D'Amico AV. The maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent

- predictor of PSA failure in radical prostatectomy specimens: validation in a cohort of 434 patients. *Am J Clin Pathol* 1999; 111: 641-644.
88. D'Amico AV, Davis A, Vargas SO, Renshaw AA, Jiroutek M, Richie JP. Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated? *Int J Radiat Oncol Biol Phys* 1999; 43: 587-590.
89. Pins MR, Jones EC, Martul V, Umlas J, Kamat BR, Renshaw AA. Metanephric adenoma-like tumors of the kidney: Report of three malignancies with emphasis on discriminating features. *Arch Pathol Lab Med* 1999; 123: 415-420.
90. Renshaw AA, Granter SR, Fletcher JA, Kozakewich HP, Corless CL, Perez-Atayde AR. Renal cell carcinomas in children and young adults: increased incidence of papillary architecture and unique subtypes. *Am J Surg Pathol* 1999; 23: 795-802.
91. Hoffman MA, Renshaw AA, Loughlin KR. Squamous cell carcinoma of the penis and microscopic margins: how much margin is needed for local cure? *Cancer* 1999; 85: 1565-1568.
92. Vargas SO, Jiroutek M, D'Amico AV, Renshaw AA. Distribution of carcinoma in radical prostatectomy specimens in the era of serum prostate-specific antigen testing: implications for delivery of localized therapy. *Am J Clin Pathol* 1999; 112: 373-376.
93. Granter SR, Renshaw AA. Cytologic analysis of renal angiomyolipoma: A comparison of radiologically classic and challenging cases. *Cancer Cytopathol* 1999; 87: 135-140.
94. Fielding JR, Visweswaran A, Silverman SG, Granter SR, Renshaw AA. CT and sonographic features of metanephric adenoma in adults. *J Comput Assist Tomogr*, 1999; 23: 441-444.
95. Renshaw AA. A practical problem with calculating the false negative rate of Papanicolaou smear interpretation by rescreening negative cases alone. *Cancer Cytopathol* 1999; 87:351-353.
96. Avery AK, Beckstead J, Renshaw AA, Corless CL. Use of antibodies RCC and CD10 in the differential diagnosis of renal neoplasms. *Am J Surg Pathol* 2000; 24: 203-210.
97. Oh WK, Manola J, Renshaw AA, Brodkin D, Loughlin KR, Richie JP, Shapiro CS, Kantoff PW. Smoking and alcohol use may be risk factors for poorer outcomes in patients with clear cell renal carcinoma. *Urology* 2000; 55: 31-35.
98. Renshaw AA, Freyer DR, Hammers YA. Metastatic metanephric adenoma in a child. *Am J Surg Pathol* 2000; 24: 570-574.

99. Renshaw AA. Compassionate conservatism in urinary cytology. *Diagn Cytopathol* 2000; 22: 137-138.
100. Reijo RA, Dorfman DM, Renshaw AA, Loughlin KR, Page, DC. DAZ family proteins exist throughout male germ cell development and transit from nucleus to cytoplasm at meiosis in humans and mice. *Biol Reprod* 2000; 63: 1490-1496.
101. Datta MW, Renshaw AA, Dutta A, Hoffman MA, Loughlin KR. Evaluation of cyclin expression in testicular germ cell tumors: cyclin E correlates with tumor type, advanced clinical stage, and pulmonary metastases. *Mod Pathol* 2000; 13: 667-672.
102. Renshaw AA. Pediatric renal cell carcinomas: Where do they fit in the new histologic classification of renal cell carcinoma? *Adv Anat Pathol* 2000; 7: 135-140.
103. Renshaw AA. Subclassifying atypical urinary cytology specimens. *Cancer Cytopathol* 2000; 90: 222-229.
104. Renshaw AA, Granter SR. Metastatic, sarcomatoid, PSA and PAP negative prostatic carcinoma. Diagnosis by fine needle aspiration. *Diagn Cytopathol* 2000; 23: 199-201.
105. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN. A pretreatment nomogram for prostate specific antigen recurrence following radical prostatectomy or external beam radiation therapy for clinically localized prostate cancer. *J Clin Oncol* 1999; 17: 168-172.
106. D'Amico AV, Renshaw AA, Arsenault L, Schultz D, Richie JP. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications on patient selection for radiation and androgen suppression therapy. *Int J Radiat Oncol Biol Phys* 1999; 45: 841-846.
107. D'Amico AV, Renshaw AA, Schultz D, Rocha S, Richie JP. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA  $\leq$  10 ng/ml and T1c,2a: Implications on patient selection for prostate only therapy. *Int J Radiat Oncol* 1999; 45: 847-851.
108. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Renshaw AA, Tomaszewski JE, Richie JP, Wein A. Optimizing patient selection for dose escalation techniques using the prostate specific antigen level, biopsy Gleason score, and clinical T-stage. *Int J Radiat Oncol Biol Phys*. 1999; 45: 1227-1233.
109. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. The clinical utility of the percent of positive prostate biopsies in defining biochemical outcome following radical prostatectomy for patients with clinically localized prostate cancer. *J Clin Oncol* 2000; 18: 1164-1172.

110. D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Hurwitz M, Kantoff P, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Utilizing prediction of early prostate specific antigen failure to optimize patient selection for adjuvant therapy trials. *J Clin Oncol* 2000; 18: 3240-3246.
111. D'Amico AV, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA. The clinical utility of the percent of positive prostate biopsies in predicting the biochemical outcome following external beam radiation therapy for patients with clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2001; 49: 679-684.
112. D'Amico AV, Wu Y, Chen M, Nash M, Renshaw AA, Richie JP. Pathologic findings and prostate specific antigen outcome following radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of Gleason score  $\leq 7$  prostate cancer. *Cancer* 2000; 89: 1810-1817.
113. D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for men with clinically localized prostate cancer. *JAMA* 2000; 284: 1280-1283.
114. Renshaw AA. Experts in Wonderland: In search of the right test and the scientific method. *Diagn Cytopathol* 2000; 23:297-298.
115. Rubin BP, Pins MR, Nielsen GP, Rosen S, Hsi BL, Fletcher JA, Renshaw AA. Isochrome 7q in adult Wilms' tumors: diagnostic and pathogenetic implications. *Am J Surg Pathol* 2000; 24: 1663-1669.
116. Renshaw AA. Measuring and reporting errors in surgical pathology: lessons from gynecologic cytology. *Am J Clin Pathol* 2001; 115: 338-341.
117. Datta MW, Macri E, Signoretti S, Renshaw AA, Loda M. Transition from *in situ* to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression. *Mod Pathol* 2001; 14: 437-442.
118. Faquin WC, Brown FM, Krane JF, Renshaw AA, Cibas ES. Extensively keratinized squamous intraepithelial lesions of the cervix are difficult to grade. *Am J Clin Pathol* 2000; 115: 80-84.
119. Renshaw AA, Lezon KM, Wilbur DC. The human false negative rate of rescreening Pap smears measured in a two arm prospective clinical trial. *Cancer Cytopathol* 2001; 93: 103-110.

120. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JR. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. *J Urol* 2001; 165: 126-129.
121. Renshaw AA, Rabaza JR, Gonzalez AM, Verdeja JC. Incidence of *Helicobacter pylori* in patients undergoing gastric bypass surgery for morbid obesity. *Obes Surg* 2001; 11: 281-283 .
122. Renshaw AA. An accurate and precise methodology for routine determination of the false negative rate of Pap smear screening. *Cancer Cytopathol* 2001; 93: 86-92.
123. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. *Mod Urol* 2000; 4: 171-177.
124. Lee AK, Schultz D, Renshaw AA, Richie JP, D'Amico AV. Optimizing patient selection for prostate monotherapy. *Int J Radiat Oncol Biol Phys* 2001; 49: 673-677.
125. Renshaw AA. Adequate histologic sampling of breast core needle biopsies. *Arch Pathol Lab Med* 2001; 125: 1055-1057.
126. Renshaw AA, Cartagena N, Schenkman RH, Derhagopian RP, Gould EW. Atypical ductal hyperplasia in breast core needle biopsies: correlation of size of the lesion, complete removal of the lesion, and the incidence of carcinoma in follow-up biopsies. *Am J Clin Pathol* 2001; 116: 92-96.
127. Renshaw AA. Improved reporting method for atypia and atypical ductal hyperplasia in breast core needle biopsies. *Am J Clin Pathol* 2001; 116: 87-94-1.
128. Renshaw AA. Estimating the percentage of Pap smears that can be reproducibly identified. Modeling Pap smear interpretation based on multiple blinded rescreenings. *Cancer Cytopathol* 2001; 93: 241-245.
129. Renshaw AA. Accuracy of thyroid fine needle aspiration using receiver operator characteristic curves. *Am J Clin Pathol* 2001; 166: 477-482.
130. Renshaw AA, Genest DR, Cibas ES. Should atypical squamous cells of undetermined significance (ASCUS) be subcategorized? Accuracy analysis of Pap smears using receiver operating characteristic curves and implications for the ASCUS/SIL ratio. *Am J Clin Pathol* 2001; 116: 692-695.
131. Renshaw AA. Predicting invasion in the excision specimen from breast core needle biopsy specimens with only ductal carcinoma in situ. *Arch Pathol Lab Med* 2002; 126: 39-41.

132. Renshaw A. Non Gyn Unknown Case #4. College of American Pathologists [cap.org/cytopath, 8/1/01].
133. Renshaw AA, Gould EW. Why there is a tendency to “overdiagnose” the follicular variant of papillary carcinoma of the thyroid. Am J Clin Pathol 2002; 117: 19-21.
134. Pitman MB, Cibas ES, Powers CN, Renshaw AA, Frable WJ. Reducing or eliminating ASCUS decreases the diagnostic accuracy of the Pap smear. Cancer Cytopathol 2002; 96: 128-134.
135. Renshaw AA. Hurthle cell carcinoma is a better gold standard than Hurthle cell neoplasm for thyroid fine needle aspirates: defining more consistent and specific cytologic criteria. Cancer Cytopathol 2002; 96: 261-265.
136. Renshaw AA, Pinnar NE, Jiroutek MR, Young ML. Quantifying the value of in-house consultation in surgical pathology. Am J Clin Pathol 2002; 117: 751-754.
137. Renshaw AA, Cartagena N, Derhagopian RP, Gould EW. Lobular neoplasia in breast core needle biopsies is not associated with an increased risk of ductal carcinoma in situ or invasive carcinoma. Am J Clin Pathol 2002; 117: 797-799.
138. D'Amico AV, Whittington R, Malkowicz SB, Renshaw AA, Tomaszewki JE, Bentley C, Schultz R, Rocha S, Wein A, Richie JP. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening. Urology 2001; 58: 406-410.
139. Renshaw AA. “Histiocytoid” cells in fine needle aspirations of papillary carcinoma of the thyroid: frequency and significance of an under-recognized cytologic pattern. Cancer Cytopathol 2002; 96: 240-243.
140. Renshaw AA. Measuring sensitivity in gynecologic cytology. A review. Cancer Cytopathol 2002; 96: 210-217.
141. Renshaw AA. Déjà vu in Pap testing: return of the 5% false negative fraction and the zero error rate. Diagn Cytopathol 2002; 26: 343-344.
142. Renshaw AA, Pinnar NE, Jiroutek MR, Young ML. Blinded review as a method for quality improvement in surgical pathology. Arch Pathol Lab Med 2002; 126: 961-963.
143. Renshaw AA. Can mucinous lesions of the breast be reliably diagnosed by core needle biopsy? Am J Clin Pathol 2002; 118: 82-84.

144. Renshaw AA. Focal features of papillary carcinoma of the thyroid in fine needle aspiration material are strongly associated with papillary carcinoma at resection. *Am J Clin Pathol* 2002; 118: 208-210.
145. Renshaw AA. Evidence based criteria for adequacy in thyroid fine needle aspiration. *Am J Clin Pathol*, in press.
146. D'Amico AV, Chen MH, Malkowicz SB, Whittington R, Renshaw AA, Tomaszewski JE, Samofalou Y, Wein A, Richie JR. Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostate specific antigen level of 4mg/ml or less. *J Urol* 2002; 167: 2025-2030.
147. D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D, Oh W, Kantoff PW. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. *Cancer* 2002; 95: 275-280.
148. D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Shultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. *Cancer* 2002; 95: 281-286.
149. Renshaw AA. How closely do thyroid fine needle aspirates need to be screened? *Diagn Cytopathol* 2002; 27: 259-260.
150. Renshaw AA, Young ML, Jiroutek MR. How many cases need to be reviewed to compare performance in surgical pathology? *Am J Clin Pathol* 2003; 119; 388-391.
151. D'Amico AV, Chen MH, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, Richie JP. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. *Int J Radiat Oncol Biol Phys* 2002; 54: 436-441.
152. Yoon JH, Chen MH, Renshaw AA, Richie JP, D'Amico AV. Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer. *Urology* 2002; 60: 454-457.
153. Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. *Urology* 2002; 60: 458-463.
154. Das P, Chen MH, Valentine K, Lopes L, Cormack RA, Renshaw AA, Tempany CM, Kumar S, D'Amico AV. Using the magnitude of PSA bounce after MRI-guided prostate

- brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. *Int J Radiat Oncol Biol Phys* 2002; 54: 698-702.
155. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. *J Clin Oncol* 2002; 20: 4567-4573.
156. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma. *Cancer* 2003; 97: 56-62.
157. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer. *Prostate Cancer Prostatic Dis* 2000; 3: 259-264.
158. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. *Cancer Cell* 2002; 1: 203-209.
159. Cross CK, Shultz D, Malkowicz SB, Huang WC, Whittington R, Tomaszewski JE, Renshaw AA, Richie JP, D'Amico AV. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. *J Clin Oncol* 2002; 20: 2863-2868.
160. D'Amico AV, Keshaviah A, Manola J, Cote K, Loffredo M, Iskrytzky O, Renshaw AA. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2002; 53: 581-587.
161. Renshaw AA, Cartagena N, Granter SR, Gould EW. Agreement and error rates using blinded review to evaluate surgical pathology of biopsy material. *Am J Clin Pathol*, in press.
162. Renshaw AA, Shultz D, Cote K, Loffredo M, Ziembra DE, D'Amico AV. Accurate Gleason grading of prostatic adenocarcinoma in prostate needle biopsies by general pathologists. *Arch Pathol Lab Med*, in press.
163. Renshaw AA. Is there a right time for cyto/histo correlation in gyn cytology? CAP Today, May 2003: 11-13.
164. Renshaw AA. Fine needle aspiration of Hurthle cell lesions – making the best of what consumers want. *Diagn Cytopathol*, in press.

165. Renshaw AA. Re-screening in cervical cytology for quality control: when bad data is worse than no data at all or what works, what doesn't, and why. *Clinics in Laboratory Medicine*, in press.

Proceedings of Meetings:

1. Gerhart TN, Renshaw AA, Hayes WC. Quantitative histology and mechanical testing of a biodegradable bone cement. In: Proceedings of the Materials Research Society Symposium. Boston, 1987; 110: 229-232.
2. Henske EP, Neumann HPH, Scheithauer BW, Short MP, Herbst EW, Renshaw A, Kwiatkowski DJ. Loss of heterozygosity studies support a tumor suppressor role for TSC2 but not TSC1. Proceedings of the Fourth Annual International Chromosome 9 Workshop, Williamsburg, VA April 1995

Book Chapters & Reviews:

1. Corson JM, Renshaw AA. Pathology of mesothelioma. In: Aisner, Arriagada, Green, Martin, Perry, eds. *Comprehensive Textbook of Thoracic Oncology*. Baltimore, MD: Williams & Wilkins, 1996; 757-778.
2. Renshaw AA, Corless CL. Prognostic features in the pathology of prostatic carcinoma. In: Kantoff, Wishnow, Loughlin, eds. *Prostate Cancer. A Multidisciplinary Guide*. Cambridge, MA: Blackwell Scientific, 1997; 11-40.
3. Renshaw AA. Detection of common infectious organisms in pulmonary specimens. *Advances in Pathology and Laboratory Medicine*, 1996; 9: 249-258.
4. Renshaw AA. Prostatic carcinoma: diagnostic pathology and prognosis. *MRI Clinics of North America*, 1996; 4: 439-448.
5. Renshaw AA, Corless CL. Papillary renal cell carcinoma. ASCP Check Sample Series in Anatomic Pathology, 1996; 24(7): 107-124.
6. Renshaw AA. CD34 and CD99: New uses in diagnostic pathology. *J Surg Pathol* 1996; 2: 3-9.
7. Renshaw AA, Fletcher CDM. Tumors of adipose tissue, muscle, cartilage, and bone. In: Barnhill, ed. *Textbook of Dermatopathology*. New York, NY: McGraw-Hill 1998; 727-746.
8. Renshaw AA. Receiver operating characteristic (ROC) curves in cytology: distinguishing differences in diagnostic accuracy from differences in diagnostic thresholds. *LabMedica International* 1998; 15: 8-9.

9. Renshaw AA. Basophilic tumors of the kidney. *J Urol Pathol* 1998; 8: 85-102.
10. Renshaw AA. Review of "Pathology of the Prostate" by CS Foster and DG Bostwick. W.B. Saunders Co. Philadelphia, PA 1998. In *Am J Surg Pathol* 1999; 23: 237-238.
11. Renshaw AA. Review of Heptinstall's Pathology of the Kidney, 5<sup>th</sup> ed. Jennette JC, Olson, JL, Schwart MM, Silva FG. In *Am J Surg Pathol* 2000; 24: 150.
12. Renshaw AA. Defining Adequacy Criteria for Pap Smears: What Constitutes an Adequate Squamous Component? LabMedica International, in press.
13. Renshaw AA. Review of Guides to Clinical Aspiration Biopsy. *Breast*, 2<sup>nd</sup> edition. Kline TS, Kline IK, Howell LP. In *Adv Anat Pathol* 2001; 8: 51-52.
14. Renshaw AA. Subtypes of renal cell carcinoma: pathologic and prognostic differences. *LabMedica International* 2000; 17: 12.
15. Renshaw AA. Review of Atlas of Gastrointestinal Endoscopy and Endoscopic Biopsies. Emory TS, Gostout CJ, Carpenter HA, Sabin LH. In *Adv Anat Pathol* 2001; 8:109-110.
16. Renshaw AA. Fine needle aspiration of the kidney. In *Cytology. Diagnostic Principles and Clinical Correlates*, 2<sup>nd</sup> edition. W. B. Saunders, Philadelphia, in press.
17. Renshaw AA. Urine cytology. In *Cytology. Diagnostic Principles and Clinical Correlates*, 2<sup>nd</sup> edition. W. B. Saunders, Philadelphia, in press.
18. Renshaw AA. Review of Atlas of Bone Marrow and Blood Pathology. Naeim F. In *Adv Anat Pathol* 2001; 8: 303.
19. Renshaw AA. Review of Head and Neck Surgical Pathology. Pilch BS, editor. In *Adv Anat Pathol* 2002; 9: 71-72.
20. Renshaw AA. Sub-classification of renal cell neoplasms: An update for the practicing pathologist. *Histopathol* 2002; 41: 283-300.
21. Renshaw AA. Review of Surgical Pathology of the Nervous System and its Coverings. Burger PC, Scheithauer BW, Vogel FS, editors, In *Adv Anat Pathol* 2003:10; 46-47.
22. Renshaw AA. Incompletely differentiated sex cord/gonadal stromal tumors in WHO Classifications of Tumours. *Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*, in press.

23. Renshaw AA. Urine and bladder washings. Cytology. Diagnostic principles and clinical correlates (2<sup>nd</sup> edition). Cibas ES and Ducatman BS, eds. Saunders. Edinburgh. 2003; 97-118.
24. Renshaw AA. Kidney and adrenal gland. Cytology. Diagnostic principles and clinical correlates (2<sup>nd</sup> edition). Cibas ES and Ducatman BS, eds. Saunders. Edinburgh. 2003; 383-404.

Abstracts and Letters:

1. Renshaw AA, Sheets EE, Constantine NM, Dinisco S, Dean B, Levine JD, Hutchinson M, Cibas ES. New Thinprep method compares favorably to conventional smears in the detection of abnormal cells [Abstract]. *Acta Cytol* 1991; 35: 589.
2. Renshaw AA, Pinkus GS, Corson JM. HBME-1 aids in distinguishing mesotheliomas and adenocarcinomas of the lung and breast [Abstract]. *Mod Pathol* 1995; 8:152A.
3. Renshaw AA, Granter SR. Fine needle aspiration of metastatic chromophobe renal cell carcinoma [Abstract]. *Acta Cytol* 1996; 40: 1087.
4. Kroll TG, Renshaw AA. Immunohistochemical distinction between poorly differentiated prostate and transitional cell carcinoma [Abstract]. *Mod Pathol* 1997; 10: 79A.
5. Pins MR, Jones EC, Martul EV, Renshaw AA. Metanephric adenoma-like renal cell carcinoma: a report of three cases [Abstract]. *Mod Pathol* 1997; 10: 85A.
6. Renshaw AA, Dean BR, Cibas ES. Causes of different ASCUS/SIL ratios among pathologists: Receiver operating characteristic curves can distinguish a differences in diagnostic accuracy from a difference in diagnostic thresholds [Abstract]. *Acta Cytol* 1997; 41: 1555.
7. Zhang Y, Rahemtulla A, Renshaw AA, Granter SR, Loda M, Nasser IA. Improved detection of breast adenocarcinoma in body fluid with the aid of mucin and immunohistochemical stains [Abstract]. *Acta Cytol* 1997; 41: 1583.
8. Renshaw AA. Adequate tissue sampling of prostate core needle biopsies (Letter). *Am J Clin Pathol* 1997; 108: 359-360.
9. Renshaw AA, Amin MB, Tickoo SK, Corless CC. Nuclear grooves in papillary (chromophil) renal cell carcinoma (letter). *Am J Surg Pathol* 1998; 22: 1298-1300.
10. Renshaw AA, Granter SR, Kozakewich HP, Perez-Atayde AR. Renal cell carcinomas in children: distinct clinicopathologic features and increased incidence of papillary architecture [Abstract]. *Mod Pathol* 1998; 11: 93A.

11. Renshaw AA, Zhang H, Weinberg DS, Loughlin KR, Fletcher JA. Genetic heterogeneity of chromophobe renal cell carcinoma: comparative fluorescence in situ hybridization, flow cytometry, and cytogenetic analysis [Abstract]. *Mod Pathol* 1998; 11: 93A.
12. Amin MB, Tickoo S, Corless C, Renshaw A. Mucin secretion in papillary renal cell carcinoma (letter). *Am J Surg Pathol* 1998; 22: 1039-1040.
13. Faquin WC, Brown FM, Krane JR, Renshaw AA, Cibas ES. A subset of keratinizing squamous intraepithelial lesions of the cervix is difficult to grade [abstract]. *Acta Cytol* 1998; 42: 1213.
14. Renshaw AA, Cronin JA, Nappi D, Whitman T, Jiroutek M, Cibas ES. Performance characteristics of rapid (30 second) prescreening: Implications for calculating the false negative rate and comparison with other quality assurance techniques [abstract]. *Acta Cytol* 1998; 42: 1239.
15. Keating J, Renshaw AA, Nasser I. Fine needle aspiration biopsy (FNAB) of the liver in patients with a history of prostatic adenocarcinoma [abstract]. *Acta Cytol* 1998; 42: 1284.
16. Renshaw AA, Jiroutek M. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens [letter]. *Cancer* 1999; 85: 1208-1210.
17. Rubin BP, Fletcher JA, Pins MR, Renshaw AA. Karyotypic differences between adult and pediatric Wilm's tumors: a study of 7 adult lesions [abstract]. *Arch Anat Cytol Pathol Clin Exp Path* 1998; 46: 432.
18. Datta MW, Renshaw AA, Dutta A, Hoffman M, Loughlin K. Evaluation of cyclin expression in testicular germ cell tumors: cyclin E correlates with tumor type and advanced clinical stage [abstract]. *Mod Pathol* 1999; 12: 92A.
19. Dry SM, Hoffman MJ, Richie JP, Renshaw AA. Justification for the 1997 American Joint Committee on Cancer staging system for stage 1 testicular germ cell tumors [abstract]. *Mod Pathol* 1999; 12: 94A.
20. Pins MR, Renshaw AA, Jones EC. Metanephric adenoma and solid tubulopapillary renal cell carcinoma: a comparative immunohistochemical analysis [abstract]. *Mod Pathol* 1999; 12: 104A.
21. Granter SR, Renshaw AA, Cibas ES. Non-tyrosine crystalloids in fine needle aspiration specimens of the parotid gland: a report of 2 cases and review of the literature (letter). *Diagn Cytopathol* 2000; 22:61.

22. Datta MW, Macri E, Signoretti S, Renshaw AA, Loda M. Loss of p53 regulated p21 expression is associated with mdm-2 expression and the development of invasive germ cell tumors (abstract). *Mod Pathol* 2000; 13: 97A.
23. Renshaw AA. Comments on “Intratesticular leiomyosarcoma in a young man after high dose doping with oral-turinabol: a case report (letter). *Cancer* 2000; 88: 2195-2197.
24. Kukoski R, Macri E, Renshaw AA, Hoffman M, Loda M, Datta MW. Functional sequestration of p27 by cyclin D2 leads to cyclin activation in testicular germ cell tumors (abstract). *Mod Pathol* 2001; 14: 115A.
25. Renshaw AA. Comments on “Follicular lesions of the thyroid. W(h)ither follicular carcinoma” (letter). *Am J Clin Pathol* 2001; 115: 782-785
26. Renshaw AA. Comments on “Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy (letter). *Cancer* 2002; 94: 2310-2311.
27. Renshaw AA. Comments on Qualification of ASCUS: a comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. *Am J Clin Pathol* 2002; 117: 333-336
28. Renshaw AA. Comments on “Assessment of morphometric measurements of prostate carcinoma volume (letter). *Cancer* 2002; 94: 2309-2310.
29. Renshaw AA. Comments on Interinstitutional review of thyroid fine needle aspirations: impact on clinical management of thyroid nodules (letter). *Diagn Cytopathol* 2002; 27: 128-129.
30. Renshaw AA, Gould E. Response to letters to the editor on “Why there is a tendency to overdiagnose the follicular variant of papillary carcinoma of the thyroid.” *Am J Clin Pathol*, in press.
31. Renshaw AA. Comments on “Misclassification of cytologic diagnoses in patients with follicular lesions or follicular neoplasms of the thyroid: implications for patient care and clinical research.” *Cancer Cytopathol*, in press.
32. Faquin WC, Cibas ES, Renshaw AA. Atypical thyroid cyst lining cells: a pitfall for the FNA diagnosis of cystic thyroid lesions (abstract). *Mod Pathol* 2003; 16: 64A.
33. Renshaw AA. Comments on “Ethical issues in anatomic pathology: are we going the way of the financial sector?” *Am J Surg Pathol*, in press.